These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9158668)

  • 1. Bilateral primary renal non-Hodgkin's lymphoma presenting with acute renal failure: successful treatment with systemic chemotherapy.
    Choi JH; Choi GB; Shim KN; Sung SH; Han WS; Baek SY
    Acta Haematol; 1997; 97(4):231-5. PubMed ID: 9158668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European experience with ifosfamide in lymphomas.
    von Kalle AK; Schaadt M; Diehl V
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):73-7. PubMed ID: 2468184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
    J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sequential alternating chemotherapy of highly malignant non-Hodgkin's lymphomas with VIM-Bleo and CHOP. Initial results].
    Steinke B; Kraft A; Reinold HM; Heim ME; Löffler B; Heidemann E; Richter C; Josten K; Bross K; Hofmann I
    Onkologie; 1989 Feb; 12(1):19-21. PubMed ID: 2469999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response-oriented therapy with CHOP and VIM-Bleo in high-grade malignant non-Hodgkin's lymphomas.
    Steinke B; Krüger HU; Kraft H; Heim ME; Günther E; Arnold H; Busch FW
    Blut; 1988 Jun; 56(6):269-71. PubMed ID: 2454690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte.
    Morel P; Dupriez B; Herbrecht R; Bastion Y; Tilly H; Delannoy A; Haioun C; Nouvel C; Bouabdallah K; Baumelou E
    Br J Cancer; 1994 Jul; 70(1):154-9. PubMed ID: 7517172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease.
    Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L
    Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary lymphoma of the kidney. Report of a case and update of the literature.
    Porcaro AB; D'Amico A; Novella G; Curti P; Ficarra V; Antoniolli SZ; Martignoni G; Matteo B; Malossini G
    Arch Ital Urol Androl; 2002 Mar; 74(1):44-7. PubMed ID: 12053451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma.
    De Lord C; Newland AC; Linch DC; Vaughan Hudson B; Vaughan Hudson G
    Hematol Oncol; 1992; 10(2):81-6. PubMed ID: 1592365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary bilateral T-cell renal lymphoma presenting with sudden loss of renal function.
    O'Riordan E; Reeve R; Houghton JB; O'Donoghue DJ; Waldek S
    Nephrol Dial Transplant; 2001 Jul; 16(7):1487-9. PubMed ID: 11427647
    [No Abstract]   [Full Text] [Related]  

  • 13. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chylothorax resulting from malignant non Hodgkin's lymphoma].
    Ohyama S; Bando K; Hasegawa Y; Taniguti M; Shirayma H
    Nihon Kokyuki Gakkai Zasshi; 1998 May; 36(5):473-7. PubMed ID: 9742867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHOP versus intensive regimens in non-Hodgkin's lymphoma.
    Longo DL; DeVita VT; Young RC
    N Engl J Med; 1993 Aug; 329(8):580-1; author reply 581-2. PubMed ID: 7687747
    [No Abstract]   [Full Text] [Related]  

  • 16. Oliguric acute kidney injury as initial presentation of renal non-Hodgkin's lymphoma infiltration.
    Leite TT; Libório AB; Silva Junior GB; Daher EF
    Saudi J Kidney Dis Transpl; 2017; 28(3):645-647. PubMed ID: 28540907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of mitoxantrone in non-Hodgkin's lymphoma.
    Armitage JO
    Oncology (Williston Park); 2002 Apr; 16(4):490-502, 507-8; discussion 511-2, 514. PubMed ID: 12017536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of non-Hodgkin's lymphoma presenting with acute renal failure diagnosed by renal biopsy].
    Yaomura T; Hayashi H; Kanoh T; Kurata K; Ishihara S; Machida H; Inaguma D; Kumon S
    Nihon Jinzo Gakkai Shi; 1999 Aug; 41(5):505-10. PubMed ID: 10502945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
    Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
    J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
    J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.